Clinical trial · Interventional
Gene Expression Profiling of Malignant Tumor Predict the Therapeutic Response of DC-CIK Immunotherapy
NCT01906632CI-TRIAL-00073796completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To investigate gene expression profile and immunological associated analysis relating to immunotherapy response of patients with malignant tumor after DC-CIK immunotherapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Malignant Tumor | Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| DC-CIK Immunotherapy | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- gene expression profile
- interventionNames
- Biological: DC-CIK Immunotherapy
Primary outcomes (1)
- measure
- T-Cell Receptor/B-Cell Receptor gene expression
- timeFrame
- 3 month
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * histologically confirmed with malignant tumor; * Age: 18-80 years; * an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2; * At least one measurable lesion according to the RECIST criteria; * Adequate bone marrow, cardiac, liver, and renal function; * Life expectancy ≥2 months; * Not received other anti-tumor treatment * Informed consent signed Exclusion Criteria: * previous history of other malignancies; * Uncontrolled central nervous system metastases; * Serious or uncontrolled concurrent medical illness.
References
Publications (0)
Data not yet available
No reference posted for this study.